Body Systems

Huntington's Disease2 Results found

Randomized, Placebo Controlled Study Of The Efficacy And Safety Of PF-02545920 In Subjects With Huntington's Disease

This study is a 26 week, randomized, parallel group, double blind comparison of PF-02545920 5 mg, PF-02545920 20 mg, and placebo dosed BID in the treatment of motor impairment of subjects with Huntington's Disease. A total of approximately 260 subjects are planned to be randomized in the study.

Principal Investigator 
Lynn A. Raymond
Body Locations and Systems 
Huntington's Disease
Area 
Vancouver
Age 
30-65

Completed Study A8241021…

This study is a 12 month open label extension study of PF-02545920 20 mg dosed BID following study A8241021 in subjects with HD. Primary endpoints will be to assess long-term safety and tolerability of 20 mg BID of PF-02545920.

Principal Investigator 
Lynn A. Raymond
Body Locations and Systems 
Huntington's Disease
Area 
Vancouver
Age 
30-66